National Institutes of Health Announces Intention with Respect to Grant of Exclusive Patent License to Emmaus Life Sciences
TORRANCE, Calif., June 25, 2020 (GLOBE NEWSWIRE) -- Emmaus Life Sciences, Inc. (OTCQB: EMMA), a leader in sickle cell disease treatment, today reported that on June 22, 2020 the National institutes of Health (NIH) issued a Notice that the National Cancer Institute, an institute of the NIH, Department of Health and Human Services, is contemplating the grant to Emmaus Medical, Inc., a subsidiary of Emmaus Life Sciences, Inc., of an Exclusive Patent License to practice the inventions embodied in the Patents and Patent Applications listed in the Supplementary Information section of the Notice. The Notice can be accessed at the following link: https://bit.ly/3erJfZz. The public will have until July 7, 2020 to comment on the proposed grant. Terms of the proposed license were not disclosed.
This patented technology is an ointment formulation comprising about 0.5% to 3.0% by weight non-acidified sodium nitrite dispersed in white petrolatum, mineral oil and bisabolol for topical administration. Nitrite anions may act as a vasodilator in vivo by generating nitric oxide in tissues with lower oxygen tension and pH. Therapeutic application of sodium nitrite through this formulation may provide selective vasodilation to hypoxemic tissue that treat ulcers associated with chronic ischemic and neuropathiculcer conditions associated with several diseases, including sickle cell disease and Type II diabetes.
“We are very pleased to be able to work with NIH and talented inventors who are committed to the discovery of innovative and new therapies. Skin ulcers are a severe, chronic and recurrent complication of sickle cell disease. We look forward to developing this promising therapy to treat skin ulcers related to sickle cell disease and other illnesses such as diabetes,” said Dr. Yutaka Niihara, M.D., M.P.H., Chairman and Chief Executive Officer of Emmaus.
About Emmaus Life Sciences